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Abstract
Over the last decade, 18F-fluorocholine positron emission tomography/computed tomography (FCH-PET/CT)
has gained in popularity for the staging and restaging of patients with prostate cancer (PCa). However, despite
abundant literature on the topic, there is a lack of publications on how to actually interpret FCH-PET/CT in a
clinical setting. Here we propose a practical, TNM-oriented approach to read FCH-PET/CT, with notes on
procedure technique, image display, review sequence and report structure. The purpose of this article is to
provide guidance to radiologists, nuclear medicine physicians and residents who are new to FCH-PET/CT, as
well as to propose an alternate approach to more experienced physicians.
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Background
Positron emission tomography/computed tomography
(PET/CT) with radiolabeled choline, a marker of cell
membrane synthesis, has proven to be a useful im-
aging technique in the management of prostate cancer
(PCa). 18F-fluorocholine (FCH) is more convenient
than 11C-choline, the tracer of reference, as it can be
delivered to centers devoid of an on-site cyclotron,
owing to the longer half-life of 18F. 11C-choline is now
FDA-approved for restaging of PCa in the setting of
biochemical relapse after radical prostatectomy [1],
and this indication is also the most established one for
FCH-PET/CT to date [2–4]. FCH-PET/CT is also useful
for initial stating of patients with high-risk PCa [2, 4].
FCH usually refers to 18F-fluoromethylcholine, but
18F-fluoroethylcholine has also been employed. Both
tracers appear to have a comparable biosdistribution
[5], although 18F-fluoromethylcholine has been used
and studied more extensively [6]. The reading ap-
proach presented here applies to both tracers.
Technique
Contrary to 18F-fluorodeoxyglucose (FDG)-PET/CT,
fasting prior to FCH-PET/CT is not required, as FCH
biodistribution and tumor uptake are not affected by gly-
cemia or insulinemia. Androgen deprivation therapy
(ADT) does not need to be stopped before FCH-PET/
CT performed in the setting of biochemical recurrence
under ADT, as castration-resistant PCa lesions are pro-
liferating despite ADT [7].
Tumor uptake and blood clearance of FCH are rapid.
Because of this a prolonged uptake period, such as
60 min when doing an FDG-PET/CT, is not mandatory
with FCH. At our center, FCH is rather injected on the
scanner table while simultaneously starting a 10-min
dynamic acquisition over the pelvis. This allows
visualization of early pathological uptake in the prostate
or the prostatic bed, as well as in the regional nodal
stations, before the urine activity enters the distal ure-
ters and bladder, thus avoiding the need for a delayed
or post-diuretic acquisition, or bladder catheterism.
The dynamic pelvic acquisition can be reconstructed in
fixed (e.g. 5 × 2 min) or progressively longer frames
(e.g. 4 × 30 s, 4 × 1 min and 2 × 2 min).
The dynamic acquisition is immediately followed by
the whole-body (WB) acquisition from skull vertex to
proximal thighs, with arms preferably upward. It is rarely
necessary to include the distal upper or lower limbs, un-
less there are known or suspected metastases beyond
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proximal part thereof. Contrary to FDG-PET/CT how-
ever, skull and brain are systematically included in FCH-
PET/CT acquisition because (1) skull is a frequent site
of axial bone metastases in PCa, and (2) brain is much
easier to assess than with FDG-PET/CT owing to the
lack of physiological FCH uptake in the normal brain.
Oral contrast can optionally be administered to better
discriminate intestinal loops and confirm physiological




At our center, WB FCH-PET/CT images are displayed
using the same viewing template and settings as for
FDG-PET/CT (Fig. 1). A viewing template that is not
too crowded allows maximizing the use of screen estate
to display the images with a decent zoom. Some nuclear
medicine software viewers offer a tab organization. In
our PET/CT template, the primary tab contains an
attenuation-corrected (AC) PET rotating maximum
intensity projection (MIP) view, 3-plane orthogonal
fused PET/CT views (transaxial, coronal, sagittal) and a
CT-only transaxial view (Fig. 1a). The non attenuation-
corrected (NAC) PET images are conveniently placed in
a secondary tab, alongside AC PET (Fig. 1b). The dy-
namic images (at least AC PET MIP and orthogonal fu-
sion views) are displayed in an additional tab or a
separate template, depending on software capabilities.
PET color maps and fusion blend
The PET-only images, including MIP, are displayed with
an inverse linear gray look-up table (LUT) color map.
When fused with CT, a rainbow LUT (e.g. “ECAT
Fig. 1 Dual-screen whole-body FCH-PET/CT image display template (Hybrid Viewer, Hermes Medical Solutions, Stockholm, Sweden). The primary
tab (a) includes AC PET MIP plus CT, PET and fused PET/CT transaxial views on the left screen, and fused sagittal and coronal views on the right
screen. The secondary tab (b) includes MIP and orthogonal views of NAC and AC PET on the left, and a large transaxial PET/CT view on the right.
A rainbow color LUT (Siemens ECAT Rainbow) is used for the fused images, which are displayed with a linear, 50–50% blend. AC PET imaged
intensity is normalized by adjusting the upper limit of the color scale so that the liver is nearly, but not, saturated (mostly yellow to orange).
The same SUV upper threshold is used to adjust the inverse gray scale intensity of the PET-only images, as well as the dynamic PET images. This is a
case of a negative FCH-PET/CT in a patient with biochemical relapse after radical prostatectomy, where physiological FCH distribution is seen
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Rainbow” found on Siemens’ systems; Fig. 1) is preferred,
as it provides more contrast over a wider dynamic range
than LUTs incorporating fewer colors (such as red and
yellow “Hot Metal” LUT). A rainbow LUT starting with
black naturally attenuates the unwanted low-level back-
ground noise. The upper end of the LUT should prefera-
bly not be white, but rather of a bright color such as red,
in order to minimize the interference with the under-
lying black and white CT signal. Furthermore, a desired
feature of the chosen rainbow LUT is a logarithmic pro-
gression, which naturally allows distinguishing uptake
level differences that are clinically meaningful, both in
the lower and the higher ends of the uptake intensity
spectrum. A rainbow LUT with these characteristics
facilitates performing most of the orthogonal slices re-
view in fusion mode. A linear blending mode with an
alpha blend of 50% should be used in fusion mode
(Fig. 1), so that both CT and PET images are equally
represented and neither modality is ever masked by the
other, particularly in areas of high uptake or density.
PET images normalization and visual uptake assessment
Unlike FDG, FCH has a relatively high physiological
uptake in the liver. Because of this, FCH images are
normalized by making the liver appear yellow to or-
ange, on average, and not saturated (Fig. 1). We find
that adjusting the inverse gray scale LUT of PET-only
images to the same upper standardized uptake value
(SUV) threshold as the color LUT provides an adequate
normalization thereof, with the same dynamic range as
color PET images. Once the whole-body PET is prop-
erly normalized, the dynamic pelvic PET images (which
do include the liver) are normalized to the same upper
SUV threshold as that of the WB PET images.
As with FDG-PET, normalizing FCH-PET images
using a fixed upper SUV threshold in all patients is not
advisable because of: (a) the inter-patient variation in
biodistribution and kinetics, (b) the weight bias affecting
SUVs, (c) potential technical errors such as erroneous
entry of weight, FCH dose and injection time, and (d)
scanner differences that can also affect SUVs. Rather, the
use of physiological uptake landmarks, such as that of
the liver and, in the case of FCH, that of exocrine glands,
appears a more rational way to normalize images con-
sistently, both across patients and within the same pa-
tient. Furthermore, such an approach to normalization
can help harmonizing inter-observer readings within and
between centers. Uptake intensity is easily qualitatively
described by comparing with such physiological land-
marks (Table 1), in a similar fashion that we have de-
scribed for 18F-fluorothymidine PET [8].
Normal FCH biodistribution
Before attempting to interpret FCH-PET/CT, one must
be familiar with the normal biodistribution and kinetics
of the tracer, which has been covered in details else-
where [9]. On the dynamic scan, the first-pass vascular
bolus is noted in the iliac arteries on the first frame(s)
and rapidly fades away. Urine activity typically reaches
distal ureters and the bladder at around 4 to 6 min, but
sometimes later.
Kidneys have a very intense physiological uptake, usu-
ally the highest among healthy organs, and are almost al-
ways saturated when PET images are normalized as
above. Liver uptake is quite intense, but less than that of
the kidneys. The uptake in spleen and major exocrine
glands (pancreas, salivary and lachrymal glands) is usu-
ally moderate and lower than that of the liver, but some-
times comparable or slightly above the latter. Bone
marrow and endocrine glands (pituitary, thyroid, adre-
nals) generally show faint to mild uptake. Uptake in the
gastro-intestinal tract is highly variable in extent and in-
tensity, and is related to the rapid turnover of mucosal
cells, in addition to probable excretion of FCH within
pancreatic juices (hypothesized from our frequent obser-
vation of continuous activity extending from the duode-
num along downstream small bowel). Skeletal and
cardiac muscles, as well as choroid plexus exhibit faint
and diffuse uptake. Marked uptake is frequently seen
along the vein proximal to injection site (Fig. 1). The
normal prostate exhibits minimal uptake.
Table 1 Proposed FCH visual uptake scale for PCa lesions
Score Uptake Qualitative terms Large lesion
(> ~ 1 cm)
Small lesiona
(≤ ~1 cm)
0 Not visible (equal to or lower than background) No uptake - -
1 Higher than background, but lower than that of the bone marrow Faint uptake Bluish -
2 Similar to or higher than that of the bone marrow, but lower than
that of the liver and exocrine glandsb
Mild uptake Greenish Bluish
3 Similar to or between that of the liver and exocrine glands Moderate uptake Yellowish Greenish
4 Higher than that of the liver and exocrine glands Intense uptake Reddish Yellowish
5 Comparable to or higher than that of the kidney Very intense uptake Red (large area of saturation) Reddish
aFor smaller lesions, the uptake score is upgraded (vs. larger lesions) to account for partial volume effect
bPancreas and salivary glands
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Interpretation
The TNM approach
A problem-oriented approach to reading FCH-PET/CT
(and oncological PET/CT in general) is better achieved
by adopting a tumor-node-metastasis (TNM) sequence
than using the typical radiological anatomical segmenta-
tion (i.e. head and neck, thorax, abdomen and pelvis).
Indeed, PET/CT being a systemic imaging primarily
used to rule in or out a systemic disease (i.e. the pres-
ence or not of metastasis), compartments delimited by
anatomic boundaries such as the thoracic inlet or the
diaphragm make little sense when describing the extent
of PCa disease. Indeed, beginning with description of
findings in head and neck area, while PCa actually origi-
nates from the pelvis and spreads upward, is counter-
intuitive. Furthermore, bone, the most frequent site of
distant metastasis in PCa, is an organ present in all
radiological segments and is more logically subdivided
into axial and appendicular skeleton in the oncological
setting. In fact, bone scan is seldom interpreted using
conventional cross-sectional anatomical divisions, as
bone metastases do not recognize those arbitrary bound-
aries. The same logic applies to FCH-PET/CT.
Accordingly, in the context of PCa, we begin by de-
scribing findings in prostate or prostatic bed, then those
in proximal to distal nodal stations relative to the pros-
tate, and finally those at potential sites of distant metas-
tases starting with the most frequent, the skeleton. For
each TNM station, a clear and concise description of
PCa-relevant positive and negative findings is warranted.
This is followed by description of incidental findings, if
any, finishing with accessory findings.
Image review order
Although the dynamic acquisition is performed first, we
find it more efficient to begin by reviewing the WB scan.
The first series to look at when opening the FCH-PET/
CT study is the WB AC-PET MIP, which is the most in-
formative and fastest to assess PET-only representation.
In just a few seconds, is it possible in the vast majority
of cases to determine the M and even N statuses on the
MIP. Even the subtlest foci of uptake can be seen in at
least a few projection angles, and can then easily be lo-
cated onto the orthogonal views with a simple mouse
click. When distant metastases are present (M1), the
patient is generally inoperable. Having this information
in mind from the start will allow the reader to be more
concise and clinically relevant when describing the loco-
regional findings. Contrary to conventional cross-
sectional imaging, PET MIP allows looking at the big
picture in a trice, i.e. seeing the forest for the trees. In a
patient with numerous metastases, the emphasis will be
on that big picture (e.g. overall tumor burden, sites in-
volved, metabolic intensity and heterogeneity, etc.),
rather than on minute loco-regional details or exact
number of lesions, which would be more important to
emphasize in a surgical case.
Following the general survey based on MIP, we proceed
with a careful review of PET/CT fused transaxial slices (re-
ferring to coronal and sagittal slices as needed). CT-only
images are consulted as needed for better locating, de-
lineating or measuring lesions of interest. Throughout
reading, CT windowing is alternated between soft tis-
sue, bone, lung and brain windows as appropriate. We
find that orthogonal AC PET-only slices are less often
consulted because rotating MIP already provides an ex-
cellent display of PET alone in a very practical format.
However, PET-only slices are sometimes helpful to dis-
tinguish between what constitutes a definite focus of
mild uptake that may suggest the presence of a small
lesion, versus non-specific heterogeneity or statistical
noise.
NAC PET images are useful for quality control pur-
poses, and to assess areas or abnormalities prone to
attenuation correction artifacts and misregistration. Re-
view of lung fields on NAC PET, where they are natur-
ally overrepresented, can improve the sensitivity to
detect or confirm small foci of uptake. We therefore
tend to review NAC images at the time of surveying
lungs for metastases. After going through the TNM se-
quence, as described below, there will be a rapid, general
survey of CT-only transaxial slices, looking for potential
incidental or accessory findings not already identified on
PET and fused images.
T: Local compartment assessment
When FCH-PET/CT is performed for primary staging,
after PCa has been proven by biopsy, we tend to review
the prostate gland with a relatively high sensitivity. Be-
cause there is proven malignancy in the prostate, any
well-defined focus of uptake raises high suspicion of ma-
lignancy, regardless of biopsy results in the concerned
sextant(s). Indeed, PCa is frequently multifocal, often bi-
lateral, and biopsy sampling errors are common [10].
However, prostatitis and benign prostate hyperplasia
have been reported as benign causes of increased FCH
uptake, and consequently correlations between intra-
prostatic FCH uptake foci and PCa lesions distribution
have yielded mixed results [2, 4]. Nevertheless, finding
that a dominant lesion is located in an area that was not
reported as involved on core biopsy may trigger the de-
cision to re-biopsy if this may alter patient management
(e.g. in the planning of brachytherapy; Fig. 2). In the set-
ting of biochemical relapse following radiotherapy or
prostatectomy, a definite focus of uptake in the prostate
or prostatic bed, respectively, would be suspicious for
local recurrence. Otherwise, normal prostate uptake is
usually faint. Any finding in the prostate area or bed on
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the WB PET must be confronted to the pelvic dynamic
series, particularly if a focal uptake abnormality is located
centrally in the prostate or at its base, and susceptible to
represent urinary activity (Fig. 3). We qualitatively de-
scribe the uptake intensity of the suspicious lesions
(Table 1), their location and extent (intraprostatic location,
seminal vesicle involvement, extraprostatic extension),
their approximate size based on PET (unless clearly
measurable on CT). We also comment on the signs of
potential local complications caused by the primary
tumor, if any, such as bladder or rectum involvement
or urinary obstruction.
N: Regional compartment assessment
PCa most commonly spreads to the periprostatic and ex-
ternal iliac nodes (including obturator nodes) before
progressing further to non-regional nodes. Dissemin-
ation through internal iliac and perirectal stations is also
possible and is considered regional spread as well. Most
of the time at least one of these nodal stations is in-
volved before PCa spreads upward to non-regional
nodes (common iliac, retroperitoneal, mediastinal,
supraclavicular) or occasionally downward to inguinal
nodes (suggesting lymph flow disturbance because of
metastatic involvement) (Fig. 4). In the setting of re-
staging following radiotherapy or pelvic lymph node
dissection, the pattern of nodal disease may differ, as
the probability of finding distant nodal metastases in
the absence regional relapse is higher. Nodal metastases
tend to be ipsilateral to the primary lesion when unilat-
eral. In FCH-PET, benign nodes have the same pattern
as that commonly seen in FDG-PET: axillary, inguinal
and mediastinal/hilar nodes having a variable degree of
uptake and which are most often symmetric in distribu-
tion. As such, isolated hyperactive inguinal nodes are
almost always benign (inflammatory or so called “react-
ive”), even more so if bilateral. Dynamic PET can help
distinguishing nodal uptake from urinary activity in the
ureter, particularly when the latter is focal instead of
curvilinear, as often seen at the crossing of the ureter
over the iliac vessels (Fig. 5).
In the presence of multiple hyperactive lesions, it is
the pattern of dissemination thereof, rather than their
level of uptake, which is most critical to determine the
probability of metastasis. However, in the presence of a
solitary lesion in an area consistent with metastatic
spread (e.g. external iliac node ipsilateral to the domin-
ant primary lesion), the level of uptake may have more
Fig. 2 FCH-PET/CT for staging and radiotherapy planning in a 78 y.o. patient with biopsy-proven PCa. Biopsy Gleason sum was 7 and PSA was
13 mg/L. MIP (a) and transaxial PET (b), fusion (c) and CT (d) views showed a moderately FCH-avid, multi-focal dominant intra-prostatic lesion in
the right prostatic lobe (red arrows), consistent with a primary PCa lesion and the biopsy findings. A second area of milder focal uptake was seen
in the left prostatic lobe (green arrows) and raised some suspicion for a contralateral PCa lesion. However, both the initial biopsy and a repeat
biopsy were negative for the presence of PCa in that area, and the patient received high dose-rate brachytherapy to the right dominant lesion
only, in addition to external radiotherapy
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Fig. 3 Restaging FCH-PET/CT in a 72 y.o. patient with biochemical relapse following radical prostatectomy. Initially, PCa Gleason sum was 9 and
left seminal vesicle was involved. PSA at time of examination was 1.6 mg/L. On whole-body MIP (a) and transaxial PET/CT fused slice (b), a focus
of uptake was not clearly distinguishable from the intense urinary activity in the bladder (red arrow). However, corresponding images from
the dynamic PET/CT (c, d) clearly showed the early appearance of a focus of moderate FCH uptake in right prostatic bed, before apparition of
urinary activity and consistent with a local relapse (green arrows). There was no evidence of metastasis and the patient was treated with
salvage radiotherapy
Fig. 4 Restaging FCH-PET/CT in a 58 y.o. patient with biochemical relapse following external beam radiotherapy. Gleason sum was 9 on initial
biopsy. PSA at time of examination was 29.3 mg/L. Whole-body MIP (a) and transaxial fusion series (b, c, d) showed intense uptake in metastatic
lymph nodes in the right paratracheal (red arrows), left para-aortic (green arrows) and bilateral iliac areas (yellow arrows)
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weight in the diagnostic decision-making process. If the
uptake of such lesion were only faint, it would be classi-
fied as more likely benign. Figure 6 illustrates a case of
bilateral pelvic nodes with faint uptake, which were
interpreted as likely negative.
Contrary to conventional imaging, there is no size cri-
terion for positivity in PET/CT. The lack of uptake in a
node >10 mm makes the latter more likely benign. On
the other hand, PET is frequently frankly positive for
nodes <10 mm.
M: Distant compartment assessment
The first organ to assess here is the skeleton, which is by
far the commonest site of distant metastasis in PCa.
Typically, bone metastases from PCa are sclerotic, but it
is not uncommon that lesions are initially lytic, particu-
larly in untreated or high-grade PCa. FCH uptake is vari-
able in bone metastases and has been shown to inversely
correlate with bone density [11]. This is consistent with
sclerotic lesions being generally less aggressive, of lower
tumor cell density, and/or having responded to therapy.
Contrary to most other cancers, spread of PCa to the
bone can be regional via the venous plexus of Batson,
resulting in bone metastases being more frequent in the
pelvis and lower spine. In addition to the location, num-
ber (approximate when numerous) and uptake features
of suspicious lesions, we also comment on their radio-
logical appearance (lytic, sclerotic or mixed), on the
presence of metabolic and/or radiological heterogeneity
among lesions, as well as on the risk of pathological frac-
ture (with lesions in weight-bearing bones, of lytic ap-
pearance, and/or involving more than 2/3 of bone width
harboring the highest risk [12]) or other complications
such as cord involvement or compression. Additionally,
the presence of bony lesions on CT that are not enhan-
cing and are thought to represent benign lesions (such
as benign bone islands) or healed metastases should be
mentioned, as they could potentially raise suspicion on
other radiological exams. Of note, the sagittal view is
particularly convenient to assess the spine, as it allows a
complete survey thereof over a very few slices. In
addition, vertebral fractures are also easily detected in
this view.
Other potential sites where metastases needs to be
ruled out include the liver, adrenals, lungs and brain,
the latter being easier to assess with FCH- than with
FDG-PET/CT, as mentioned earlier. The sensitivity of
FCH-PET/CT for small liver metastases is reduced, as
Fig. 5 Restaging FCH-PET/CT in a 68 y.o. patient with biochemical relapse following radical prostatectomy. Initially, PCa Gleason sum was 7. PSA
was 0.35 mg/L at time of examination. Whole-body MIP (a) and transaxial fusion slices (b, c) showed two foci of moderate uptake in the right iliac
nodal area (red arrows) that were initially perceived as suspicious for nodal relapse. However, dynamic PET MIP (d) and fusion series (e) showed
no early focal activity at either site, which was consistent with urinary activity on the whole-body scan. This study was interpreted as negative
and the patient underwent salvage radiotherapy
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they either need to exhibit a level of uptake that is su-
perior to that of the liver, or to be large enough so that
significant uptake can be evidenced with confidence
and despite spill-in from surrounding liver activity. Be-
cause liver metastases are relatively infrequent in PCa, this
remains a relatively minor drawback of FCH-PET/CT.
If there is no evidence of metastasis, a simple phrase
such as “There are no foci of increased uptake elsewhere
that are suspicious for metastases, in particular in the
bones” will concisely summarize relevant negative find-
ings. Because at our institution CT performed as part of
a PET/CT procedure is acquired at low amperage, with-
out IV contrast and in free-breathing conditions, our
focus is not on trying to find – or exclude the presence
of – any small lesion without detectable FCH uptake,
which could otherwise be better visualized on a fully
diagnostic CT or MRI scan. Considering that the nega-
tive predictive value of FCH-PET/CT has been shown to
be superior to that of conventional imaging [2, 3], such
small lesions without detectable FCH uptake are less
likely to be clinically relevant.
Incidental and accessory findings
An incidental finding is a condition unrelated to that for
which the FCH-PET/CT was requested, and which pres-
ence was unknown before the procedure. It differs from
an accessory finding in that it may potentially alter pa-
tient management. FCH uptake is not specific to PCa,
and most cancers other that PCa can also exhibit FCH
uptake. An FCH-avid lesion in a location that is atypical
for PCa spread – particularly in the absence of more
typically located metastases elsewhere – should raise the
possibility of a synchronous malignancy. Depending on
the context of the patient, further investigation of such
an incidental finding may or may not be clinically rele-
vant. Other incidental findings that are more easily de-
tected on CT (even on low-dose CT) include potentially
Fig. 6 Restaging FCH-PET/CT in a 68 y.o. patient with biochemical relapse following radical prostatectomy. Initially, PCa Gleason sum was 8. PSA
was 0.48 mg/L at time of examination. Transaxial PET (a, b), fusion (c, d) and CT (e, f) slices showing faint activity in left paravesical (red arrows)
and right external iliac (green arrows) enlarged lymph nodes. However, the very low uptake in the latters was suggestive of a benign process,
such as inflammatory or reactive nodes. This study was interpreted as negative and the patient underwent salvage radiotherapy
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life-threatening conditions such as a large vascular
aneurysm, a pneumothorax or a cavity effusion.
Accessory findings are abnormalities of lesser clinical
interest to the referring physician, which do not fall
under the PCa-relevant positive or negative findings, or
incidentalomas categories. Virtually any benign lesions,
traumatic or inflammatory processes that can demon-
strate hypermetabolism with FDG can also exhibit in-
creased FCH uptake to a variable extent. Again and
again, it is the distribution pattern of hyperactive le-
sions that is the most determinant factor in the diag-
nostic decision-making process. Uptake intensity may
modulate the level of suspicion of malignancy, but is
not diagnostic by itself. CT appearance is often helpful
to increase the level of confidence. For example, an
FCH-avid adrenal nodule will confidently be classified
as a benign adenoma in the presence of a low attenu-
ation on non-contrast low-dose CT. Other examples of
accessory findings include FCH uptake related to osteo-
arthritis, hilar and mediastinal reactive lymph nodes,
reactive bone marrow (diffuse uptake), and traumatic
lesions. Accessory findings detected on CT only, i.e.
without metabolic correlate, include surgical sequella
unrelated to PCa (of which cholecystectomy is probably
be the most common), vascular calcifications, steatosis,
renal or liver cysts, and old fractures, just to name a
few.
A normal structure with an FCH uptake within normal
range should not be described. This only lengthens the
report, without adding clinical value. Finally, for the rea-
sons mentioned earlier concerning low-dose CT, we do
not describe any organ as having a “normal” appearance
on CT, as a fully diagnostic CT could contradict this.
SUV
Tumor SUVs are not systematically reported because
they have not consistently been shown to improve diag-
nostic accuracy over qualitative interpretation. There is
no clinically proven FCH SUV cutoff that can rule in or
out malignancy. SUV is heavily influenced by the partial
volume effect. PET can detect small, even sub-cm metas-
tases, but SUV will inevitably be lower in such lesions.
Visual assessment may, at least partly, overcome this
limitation (Table 1).
SUVs are useful in research as a continuous quantita-
tive variable to be correlated with tumor or patient char-
acteristics or outcomes in a given population. But, in the
clinical setting, the only utility of SUV is to compare up-
take values between repeat studies in the same patient,
e.g. for therapeutic response assessment. Even then,
SUV comparison remains in support of qualitative up-
take assessment, and is valid only if the current and
prior studies are normalized to a similar SUV upper
threshold, implying that the organ of reference’s uptake
is stable. While a SUV difference of 30% is generally
considered significant, i.e. unlikely due to chance [13], it
is our experience that such a difference is easily picked
up visually when images are properly normalized. Fur-
thermore, complete molecular response remains a visual
criterion, as SUV can virtually never reach zero. Hence,
SUV comparisons have a limited added value other than
illustrating the amplitude of the lesion’s partial response
or progression.
In the end, in the oncologic setting, the foremost im-
portant feature of scintigraphic abnormalities, before
considering any uptake quantification, is their distribu-
tion pattern relative to each other and to the primary
tumor. A high-uptake lesion in an uncommon location
for a metastasis is most often not one, particularly if no
other more typically located metastases are found. Like-
wise, a definite focus of mild uptake in a rounded sub-
cm lymph node in the obturator area ipsilateral to the
primary PCa lesion will raise some suspicion of metas-
tasis, regardless of the actual SUV. In both situations,
PCa-specific pattern recognition and clinical judgment
are key to accurate diagnosis, not SUVs. In our experi-
ence, consistent qualitative appreciation of uptake
intensity (e.g. as in Table 1) instead of systematically
reporting SUVs has many advantages: (1) it avoids pit-
falls related to SUV measurements, (2) it minimizes the
too often overstated importance of SUVs and (3) it
makes the report more concise.
Report structure
Our reports are divided in 4 sections, as follows:
Clinical information section
Clinical information available at the time of reporting
should be summarized. This includes the relevant infor-
mation gathered from the requisition form (including
the clinical question to be answered), the patient ques-
tionnaire and interview, the medical record, or the
treating team. Details about the pathology results (in-
cluding Gleason score), prior and current treatments,
other imaging findings, biochemical status (PSA and, if
relevant, PSA doubling time) and symptoms that are
relevant for the interpretation of the FCH-PET/CT scan
should be mentioned.
Technique section
This section is brief and limited to few sentences. It is
not necessary to mention every technical detail that can
be found elsewhere, in the standard procedure protocol
or patient imaging record, unless there has been a sig-
nificant protocol deviation that could potentially impact
on the quality of the scan. We favor a brief statement
about the imaging sequence and technique, the areas
surveyed, and the use of contrast or drug if any. For
Beauregard and Beaulieu Cancer Imaging  (2016) 16:41 Page 9 of 11
example: “At the time of FCH administration, we started
a 10-min dynamic PET acquisition over the pelvis, which
was followed by a whole-body acquisition from vertex to
proximal thighs. Both acquisitions were accompanied by
a low-dose CT with oral contrast for anatomical correl-
ation and attenuation correction.”
Observations section
The observation section describes the relevant positive
and negative findings in a TNM sequence, as detailed
earlier. For simpler cases, one paragraph is generally suf-
ficient, while for more complex cases T, N and M com-
partments can be separated in distinct paragraphs. The
emphasis is on the description of the findings, rather
than opinions.
If there were any incidental finding, its description
would come thereafter, in a separate paragraph. This is
followed by description of accessory findings, starting
with “Accessorily, …”. Because accessory findings are
most of the time benign and unrelated to the onco-
logical condition, their description should be succinct.
Further, for these we tend to formulate a diagnostic
opinion together with the description within the Obser-
vations section, particularly for obviously benign find-
ings that would be superfluous to point out again in the
conclusion. An example of this could be: “There is mild
uptake in multiple hilar and mediastinal lymph nodes,
which are symmetric in distribution and thus likely of
inflammatory or granulomatous etiology.”
In the case of a repeat study, to assess either the evo-
lution under observation or the therapeutic response,
the description should focus on the metabolic (and sec-
ondarily anatomic) evolution of previously seen PCa le-
sions, as well as the apparition of new suspicious lesions
if any. We would also comment on the homogeneity or
heterogeneity of lesions’ evolution or response. Here
there is no need to mention again all accessory findings
if they are stable and clinically irrelevant. A simple state-
ment such as “The remainder of the scan shows the same
accessory findings as previously described. No other sig-
nificant changes are seen as compared to the previous
study” can be used instead.
Conclusion section
This is the most important section of the report, and in
the majority of cases, the only one the referring phys-
ician will ever read. Conclusion should straightforwardly
answer the clinical question, which is typically to stage
or restage PCa. Hence, the first sentence(s) should for-
mulate as concisely as possible an opinion on what the
TNM stage is. Completely equivocal opinions should be
avoided as much as possible. In those more difficult
cases, the arguments for and against a given hypothesis
can be summarized in the conclusion, ending up with a
likelihood statement about the hypothesis. These argu-
ments may include clinical information affecting the
probability of a positive (or negative) finding being truly
positive (or negative). For example, it has been demon-
strated that a high Gleason score, a high PSA and a
short PSA doubling time are associated with higher sen-
sitivity of FCH-PET/CT [4]. Hence, an equivocal finding
based on FCH-PET/CT images alone, such as a solitary
pelvic lymph with a rather mild FCH uptake, could be
interpreted as more likely to represent metastasis in a
patient with any of these characteristics, or less likely to
in a patient with none.
Opinion on the probable nature of any incidental find-
ing is given thereafter. However, accessory findings are
only mentioned in the conclusion if they are likely to
alter patient care. For example, we seldom mention the
presence of cholecystectomy sequela in the Conclusion
section of an oncological PET/CT report.
Organization of conclusion in a bulleted list is pre-
ferred and improves readability. Repeating findings’ de-
scription is avoided as much as possible. Differential
diagnoses are typically limited to the few most likely
ones, in order of probability. When relevant, appropriate
next diagnostic steps are proposed. For example, a typ-
ical conclusion looks like this:
 The findings are consistent with a primary prostate
cancer lesion extending over the middle and apical
sextants of the left prostatic lobe, accompanied by
two nodal metastases in the left external iliac area.
 No evidence of osseous or visceral metastases.
 Incidental finding of a thyroid nodule with moderate
uptake in the right thyroid lobe, for which a primary
thyroid malignancy cannot be ruled out. This could
further be investigated with ultrasound and
fine-needle biopsy if clinically relevant in the
setting of this patient.
If FCH-PET/CT is performed for therapeutic response
assessment, the conclusion could be as simple as:
 The findings are consistent with a complete
metabolic response.
Conclusion
In summary, FCH-PET/CT for PCa is read and re-
ported in a similar fashion as oncological FDG-PET/
CT. For the experienced FDG-PET/CT reader, the
learning curve is rapid, and involves mastering the nor-
mal biodistribution of FCH, the dissemination pattern
of PCa, and benign pathologies exhibiting FCH uptake
(largely overlapping with those associated with FDG
uptake). Reviewing the dynamic PET images may be
challenging at first, as not all software viewers are user-
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friendly for this purpose. However, there are overall
more similarities than differences between reporting
oncological FCH- and FDG-PET/CT. For both, we en-
courage adopting a problem-oriented approach based
on the TNM system, in combination with a concise
reporting style clearly addressing the clinical question
upfront, both in the Observations and Conclusion sec-
tions. In our opinion, this makes PET/CT reading more
efficient for the nuclear medicine physician and radi-
ologist, and report clearer and more clinically relevant
for the referring physician or surgeon.
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